Pooled Analysis of Two Randomized Trials Comparing Titanium-nitride-oxide-coated Stent Versus Drug-eluting Stent in ST Elevation Myocardial Infarction

Petri O. Tuomainen, a,b Jussi Sia, c Wail Nammas, b Matti Niemelä, d Juhani K.E. Airaksinen, e Fausto Biancari, f and Pasi P. Karjalainen b,*

aDepartment of Internal Medicine and Heart Center, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland
bDepartment of Cardiology, Satakunta Central Hospital, Pori, Finland
cDepartment of Cardiology, Kokkola Central Hospital, Kokkola, Finland
dDepartment of Internal Medicine, Division of Cardiology, University of Oulu, Oulu, Finland
eDepartment of Medicine, Turku University Hospital, Turku, Finland
fDivision of Cardiothoracic and Vascular Surgery, Department of Surgery, Oulu, Finland

*Correspondence

Table 1
Baseline Clinical Characteristics of the Two Study Groups in the TITAX-AMI Trial

<table>
<thead>
<tr>
<th>Variable</th>
<th>BAS group N=83</th>
<th>DES group N=97</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>63.3 (10.5)</td>
<td>62.0 (11.8)</td>
<td>.43</td>
</tr>
<tr>
<td>Male gender</td>
<td>60 (72.3)</td>
<td>77 (79.4)</td>
<td>.27</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>36 (43.4)</td>
<td>47 (48.5)</td>
<td>.50</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>12 (14.5)</td>
<td>9 (9.3)</td>
<td>.28</td>
</tr>
<tr>
<td>Hypertension</td>
<td>41 (49.4)</td>
<td>45 (46.4)</td>
<td>.69</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>47 (56.6)</td>
<td>68 (70.1)</td>
<td>.06</td>
</tr>
<tr>
<td>Current smoking</td>
<td>27 (32.5)</td>
<td>43 (44.3)</td>
<td>.11</td>
</tr>
<tr>
<td>Prior MI</td>
<td>10 (12.0)</td>
<td>6 (6.2)</td>
<td>.17</td>
</tr>
<tr>
<td>Prior PCI</td>
<td>4 (4.8)</td>
<td>4 (4.1)</td>
<td>.82</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>4 (4.8)</td>
<td>0 (0)</td>
<td>.03</td>
</tr>
<tr>
<td>Prior stroke</td>
<td>1 (1.2)</td>
<td>4 (4.1)</td>
<td>.23</td>
</tr>
</tbody>
</table>

BAS, bioactive stent; DES, drug-eluting stent; CABG, coronary artery bypass grafting; CAD indicates coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.

Continuous variables are presented as mean (standard deviation), while categorical variables are presented as frequency (percentage).
Table 2

Baseline Clinical Characteristics of the Two Study Groups in the BASE-ACS Trial

<table>
<thead>
<tr>
<th>Variable</th>
<th>BAS group</th>
<th>DES group</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=162</td>
<td>N=159</td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>61.9 (12.0)</td>
<td>61.5 (12.5)</td>
<td>.79</td>
</tr>
<tr>
<td>Male gender</td>
<td>128 (79.0)</td>
<td>121 (76.1)</td>
<td>.53</td>
</tr>
<tr>
<td>Family history of CAD</td>
<td>75 (46.3)</td>
<td>60 (37.7)</td>
<td>.12</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>23 (14.2)</td>
<td>24 (15.1)</td>
<td>.82</td>
</tr>
<tr>
<td>Hypertension</td>
<td>54 (33.3)</td>
<td>61 (38.4)</td>
<td>.35</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>50 (30.9)</td>
<td>55 (34.6)</td>
<td>.48</td>
</tr>
<tr>
<td>Current smoking</td>
<td>73 (45.1)</td>
<td>66 (41.5)</td>
<td>.52</td>
</tr>
<tr>
<td>Prior MI</td>
<td>13 (8.0)</td>
<td>8 (5.0)</td>
<td>.28</td>
</tr>
<tr>
<td>Prior PCI</td>
<td>5 (3.1)</td>
<td>12 (7.5)</td>
<td>.07</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>5 (3.1)</td>
<td>2 (1.3)</td>
<td>.26</td>
</tr>
<tr>
<td>Prior stroke</td>
<td>5 (3.1)</td>
<td>2 (1.3)</td>
<td>.26</td>
</tr>
</tbody>
</table>

BAS, bioactive stent; DES, drug-eluting stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation.

Continuous variables are presented as mean (SD), while categorical variables are presented as frequency (percentage).
### Table 3

Angiographic and Procedural Data of the Two Study Groups in the TITAX-AMI Trial

<table>
<thead>
<tr>
<th>Variable</th>
<th>BAS group N=83</th>
<th>DES group N=97</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vessel type</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left anterior descending artery</td>
<td>49 (59.0)</td>
<td>39 (40.2)</td>
<td>.01</td>
</tr>
<tr>
<td>Left circumflex artery</td>
<td>4 (4.8)</td>
<td>21 (21.6)</td>
<td>.001</td>
</tr>
<tr>
<td>Right coronary artery</td>
<td>28 (33.7)</td>
<td>36 (37.1)</td>
<td>.64</td>
</tr>
<tr>
<td>Left main coronary artery</td>
<td>0 (0)</td>
<td>1 (1.0)</td>
<td>.35</td>
</tr>
<tr>
<td>Saphenous venous graft</td>
<td>2 (2.4)</td>
<td>0 (0)</td>
<td>.12</td>
</tr>
<tr>
<td><strong>Thrombus</strong></td>
<td></td>
<td></td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Reference vessel diameter, mean (SD), mm</td>
<td>3.26 (0.44)</td>
<td>3.20 (0.47)</td>
<td>.52</td>
</tr>
<tr>
<td>Lesion length, mean (SD) mm</td>
<td>14.3 (5.5)</td>
<td>12.5 (5.3)</td>
<td>.01</td>
</tr>
<tr>
<td>Stent diameter, mean (SD), mm</td>
<td>3.38 (1.15)</td>
<td>3.17 (0.44)</td>
<td>.10</td>
</tr>
<tr>
<td>Stent length, mean (SD), mm</td>
<td>18.1 (4.5)</td>
<td>17.4 (4.9)</td>
<td>.23</td>
</tr>
<tr>
<td>Total stent length, mean (SD), mm</td>
<td>19.3 (6.5)</td>
<td>17.9 (6.0)</td>
<td>.14</td>
</tr>
<tr>
<td>Number of stents per culprit lesion, mean (SD)</td>
<td>1.11 (0.31)</td>
<td>1.06 (0.28)</td>
<td>.30</td>
</tr>
<tr>
<td>Thrombus aspiration</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>NA</td>
</tr>
<tr>
<td>Direct stenting</td>
<td>11 (13.3)</td>
<td>18 (18.6)</td>
<td>.33</td>
</tr>
<tr>
<td>Post-dilatation</td>
<td>40 (48.2)</td>
<td>38 (39.2)</td>
<td>.22</td>
</tr>
<tr>
<td><strong>Medications</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-molecular weight heparin</td>
<td>81 (97.6)</td>
<td>92 (94.8)</td>
<td>.34</td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>1 (1.2)</td>
<td>1 (1.0)</td>
<td>.91</td>
</tr>
<tr>
<td>Glycoprotein IIb/IIIa inhibitor</td>
<td>55 (66.3)</td>
<td>56 (57.7)</td>
<td>.24</td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>1 (1.2)</td>
<td>2 (2.1)</td>
<td>.65</td>
</tr>
</tbody>
</table>

BAS, bioactive stent; DES, drug-eluting stent; NA, not available; SD, standard deviation.

Continuous variables are presented as mean (standard deviation), while categorical variables are presented as frequency (percentage).
Table 4

Angiographic and Procedural Data of the Two Study Groups in the BASE-ACS Trial

<table>
<thead>
<tr>
<th>Variable</th>
<th>BAS group N=162</th>
<th>DES group N=159</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vessel type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left anterior descending artery</td>
<td>66 (40.7)</td>
<td>79 (49.7)</td>
<td>.11</td>
</tr>
<tr>
<td>Left circumflex artery</td>
<td>27 (16.7)</td>
<td>30 (18.9)</td>
<td>.61</td>
</tr>
<tr>
<td>Right coronary artery</td>
<td>68 (42.0)</td>
<td>50 (31.4)</td>
<td>.05</td>
</tr>
<tr>
<td>Left main coronary artery</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>NA</td>
</tr>
<tr>
<td>Saphenous venous graft</td>
<td>1 (0.6)</td>
<td>0 (0)</td>
<td>.32</td>
</tr>
<tr>
<td>Thrombus</td>
<td>125 (77.2)</td>
<td>114 (71.7)</td>
<td>.26</td>
</tr>
<tr>
<td>Reference vessel diameter, mean (SD), mm</td>
<td>3.11 (0.40)</td>
<td>3.13 (0.41)</td>
<td>.57</td>
</tr>
<tr>
<td>Lesion length, mean (SD), mm</td>
<td>14.7 (5.0)</td>
<td>15.0 (7.4)</td>
<td>.72</td>
</tr>
<tr>
<td>Stent diameter, mean (SD, mm)</td>
<td>3.13 (0.40)</td>
<td>3.14 (0.41)</td>
<td>.89</td>
</tr>
<tr>
<td>Stent length, mean (SD), mm</td>
<td>18.5 (5.0)</td>
<td>18.7 (5.4)</td>
<td>.72</td>
</tr>
<tr>
<td>Total stent length, mean (SD), mm</td>
<td>22.2 (10.2)</td>
<td>20.4 (7.6)</td>
<td>.14</td>
</tr>
<tr>
<td>Number of stents per culprit lesion, mean (SD)</td>
<td>1.17 (0.41)</td>
<td>1.13 (0.33)</td>
<td>.44</td>
</tr>
<tr>
<td>Thrombus aspiration</td>
<td>71 (43.8)</td>
<td>66 (41.5)</td>
<td>.67</td>
</tr>
<tr>
<td>Direct stenting</td>
<td>73 (45.1)</td>
<td>67 (42.1)</td>
<td>.60</td>
</tr>
<tr>
<td>Post-dilatation</td>
<td>65 (40.1)</td>
<td>70 (44.0)</td>
<td>.48</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low-molecular weight heparin</td>
<td>68 (42.0)</td>
<td>62 (39.0)</td>
<td>.59</td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>39 (24.1)</td>
<td>50 (31.4)</td>
<td>.14</td>
</tr>
<tr>
<td>Glycoprotein IIb/IIIa inhibitor</td>
<td>64 (39.5)</td>
<td>67 (42.1)</td>
<td>.63</td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>54 (33.3)</td>
<td>46 (28.9)</td>
<td>.39</td>
</tr>
</tbody>
</table>

BAS, bioactive stent; DES, drug-eluting stent; NA, not available; SD, standard deviation.

Continuous variables are presented as mean (standard deviation), while categorical variables are presented as frequency (percentage).